> ## Content Index
> Fetch the complete content index at: https://redfiled.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# INTELLIA Lands Up to $400M Non-Dilutive Debt Facility From OrbiMed
- URL: https://redfiled.com/intellia-lands-up-to-400m-non-dilutive-debt-facility-from-orbimed/
- Published: 2026-09-04T14:52:37.000Z
- Updated: 2026-09-04T15:34:48.000Z
- Description: The CRISPR company drew $75 million at closing, with $325 million more tied to milestones ahead of a planned U.S. launch of lonvo-z in hereditary angioedema.
- Author: William Hayes
- Tags: NTLA, Other

**Intellia Therapeutics (NTLA)** said on **September 4, 2026** that it has entered into a **$400 million non-dilutive senior secured term loan facility** with healthcare investment firm **OrbiMed**. An initial term loan of **$75 million was funded at closing**, with the remainder tied to milestones and mutual agreement over a **five-year term**.

The structure breaks down into three parts: the **$75 million upfront tranche**, **five additional tranches totaling up to $225 million** that Intellia can draw at its option upon hitting specified milestones tied primarily to lonvoguran ziclumeran, and a further **$100 million** available only *subject to mutual agreement between the parties*.

The financing is aimed at carrying the company through what it calls anticipated value inflection points, including a **planned U.S. approval and commercial launch of lonvo-z** as a one-time treatment for **hereditary angioedema (HAE)**.

Chief Financial Officer **Edward Dulac** said lonvo-z has *the potential to transform the treatment paradigm for people living with HAE as well as the future capital needs of our company*, adding that the non-dilutive structure lets Intellia execute its launch plan and advance **nexiguran ziclumeran** in transthyretin amyloidosis. OrbiMed General Partner **Matthew Rizzo** described Intellia as a leader in *the in vivo gene editing revolution*.

Lonvo-z, formerly NTLA-2002, is an in vivo CRISPR/Cas9 candidate designed to permanently lower kallikrein by inactivating the **KLKB1 gene** with a **single outpatient dose**. It carries **five regulatory designations**: Orphan Drug and RMAT from the FDA, the U.K. MHRA's Innovation Passport, EMA PRIME status and Orphan Drug Designation from the European Commission.

**TD Cowen** acted as exclusive financial advisor to Intellia, with Goodwin Procter as legal counsel and Covington & Burling advising OrbiMed. Full terms of the loan agreement will be filed with the SEC on a **Form 8-K**.

Intellia flagged the usual caveats: there is no assurance it will hit the milestones needed to access the additional **$225 million**, that the extra **$100 million** will be agreed, or that the debt-service obligations, restrictive covenants and security interests attached to the facility will not constrain it.

[NTLA stock price](https://www.tradingview.com/?ref=redfiled.com) by TradingView

This is a factual summary of a public filing or press release, not investment advice. Verify all figures against the source before acting on them.